サル痘治療薬の世界市場 - 業界規模、シェア、動向、機会、予測：治療別、エンドユーザー別、地域別（2017年～2027年）

世界のサル痘治療薬の市場規模は、2023年～2027年の予測期間中に大幅なCAGRでの成長が予測されています。

市場の成長は、欧米の人々の間でウイルス感染症が突然発生したことに起因する可能性があります。

当レポートでは、世界のサル痘治療薬市場について調査分析し、セグメント別の予測、地域別の分析、競合情勢などを提供しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のサル痘治療薬市場に対するCOVID-19の影響

第5章 顧客の声

• 一般に観察されるサル痘の症状
• サル痘の有病率：性別
• サル痘の有病率：年齢層別
• サル痘の有病率：地域別

第6章 世界のサル痘治療薬市場の見通し

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 治療別（天然痘ワクチン、抗ウイルス薬、ワクシニア免疫グロブリン（VIG））
  • エンドユーザー別（病院、専門診療所、外来手術センター、その他）
  • 企業別（2021年）
  • 地域別
• 製品市場マップ

第7章 北米のサル痘治療薬市場の見通し

• 市場規模と予測
• 市場シェアと予測
• 北米：国別分析
  • 米国のサル痘治療薬市場の見通し
  • カナダのサル痘治療薬市場の見通し

第8章 欧州のサル痘治療薬市場の見通し

• 市場規模と予測
• 市場シェアと予測
• 欧州：国別分析
  • 英国のサル痘治療薬市場の見通し
  • ドイツのサル痘治療薬市場の見通し
  • フランスのサル痘治療薬市場の見通し
  • ベルギーのサル痘治療薬市場の見通し
  • オランダのサル痘治療薬市場の見通し
  • スウェーデンのサル痘治療薬市場の見通し
  • イタリアのサル痘治療薬市場の見通し
  • スペインのサル痘治療薬市場の見通し

第9章 アジア太平洋のサル痘治療薬市場の見通し

• 市場規模と予測
• 市場シェアと予測
• アジア太平洋：国別分析
  • オーストラリアのサル痘治療薬市場の見通し
  • シンガポールのサル痘治療薬市場の見通し

第10章 中東・アフリカのサル痘治療薬市場の見通し

• 市場規模と予測
• 市場シェアと予測
• 中東・アフリカ：国別分析
  • ナイジェリアのサル痘治療薬市場の見通し

第11章 市場力学

• 促進要因
• 課題

第12章 市場の動向と発展

第13章 競合情勢

• 企業プロファイル
  • Chimerix Inc.
  • SIGA Technologies, Inc.
  • Emergent BioSolutions Inc.
  • Bavarian Nordic A/S
  • Hetero Drugs Limited
  • Mylan N.V.
  • Piramal Enterprises Limited
  • Olon S.p.A.
  • Teva Pharmaceutical Industries Limited
  • CIDIC Company Limited

第14章 戦略的推奨事項

Global monkeypox therapeutics market is projected to register growth at a significant CAGR during the forecast period, 2023-2027. The market growth can be attributed to the sudden outburst of the viral infection among the population across Europe and United States. In the year 2003, monkeypox caused a commotion because it spread quickly, and the number of affected patients exceeded 40 in a matter of weeks. Although the disease spread was relatively well-controlled, the recent outbreak of infection and rapidly increasing cases pose a threat for another possible pandemic. Hence, the demand for effective treatment, vaccination, and other rare disease therapeutics are expected to support the growth of the global monkeypox therapeutics market over the next five years.

There is currently no specific treatment or defined pharmaceutical for the disease, but symptomatic treatment is possible, and an increase in demand for pain and itch relief due to boils and rashes are positively influencing the growth of the global monkeypox therapeutics market.

Monkeypox is a viral infection that spreads like a highly communicable disease through mere touch and use of infected patient's material. The virus is related to smallpox, and the vaccination and drugs used to control smallpox are also somewhat effective against monkeypox diseases. Although no specific vaccine or treatment drug has yet been commercialised, research is still ongoing. Patients with compromised immunity, those suffering from chronic disease, certain skin conditions such as eczema, those recovering from a recent pandemic, and those suffering from other anti-viral infections are all at high risk of contracting the monkeypox.

Growing demand for timely vaccines and potential disease treatments may support the growth of the global monkeypox therapeutics market in the next five years. Governments are actively investing in the research and development of effective vaccines and drugs to control disease spread and treat affected patients. In addition, the government is taking steps to promote drug development using genetic engineering tools in order to provide vaccination in the event that the virus evolves and affects a larger portion of the population.

Genomic sequencing for the virus would elucidate the specific infection-causing sequences, which could aid in the early diagnosis of the viral infection and the development of effective vaccines for the population at risk of infection in the coming years. Furthermore, rising healthcare expenditures by the population is fuelling growing investments for the developmen to new vaccines, which is likely to aid the global monkeypox therapeutics market in the next five years.

The global monkeypox therapeutics market segmentation is based on treatment, end user, regional distribution, and competitive landscape. Based on treatment, the market is divided into smallpox vaccine, antivirals, and vaccinia immune globulin (VIG). The smallpox vaccine segment is anticipated to hold the largest share in the global monkeypox therapeutics market due to the rising number of cases of monkeypox.

Key players operating in the global monkeypox therapeutics market are Chimerix Inc., SIGA Technologies, Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Hetero Drugs Limited, Mylan N.V., Piramal Enterprises Limited, Olon S.p.A., Teva Pharmaceutical Industries Limited, CIDIC Company Limited, among others.

Years considered for this report:

Historical Years: 2017-2020

Base Year: 2021

Estimated Year: 2022

Forecast Period: 2023-2027

Objective of the Study:

• To analyze the historical growth in the market size of the global monkeypox therapeutics from 2017 to 2021.
• To estimate and forecast the market size of global monkeypox therapeutics market from 2023 to 2027 and growth rate until 2027.
• To classify and forecast the global monkeypox therapeutics market based on treatment, end user, region, and company.
• To identify the dominant region or segment in the global monkeypox therapeutics market.
• To identify drivers and challenges for the global monkeypox therapeutics market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the global monkeypox therapeutics market.
• To identify and analyze the profiles of leading players operating in the global monkeypox therapeutics market.
• To identify key sustainable strategies adopted by market players in global monkeypox therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of the Global monkeypox therapeutics market using a top-down approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

• Market research and consulting firms
• Government bodies such as regulating authorities and policy makers
• Organizations, forums, and alliances

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global monkeypox therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Monkeypox Therapeutics Market, By Treatment:

Smallpox Vaccine

Antivirals

Vaccinia Immune Globulin (VIG)

• Monkeypox Therapeutics Market, By End User:

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Others

• Monkeypox Therapeutics Market, By Region:

North America

• United States
• Canada

Asia-Pacific

• Australia
• Singapore

Europe

• France
• Germany
• United Kingdom
• Belgium
• Netherlands
• Sweden
• Italy
• Spain

Middle East & Africa

• Nigeria

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global monkeypox therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Monkeypox Therapeutics Market

5. Voice of Customer

• 5.1. Commonly Observed Symptoms of Monkeypox
• 5.2. Monkeypox Prevalence, By Gender
• 5.3. Monkeypox Prevalence, By Age Group
• 5.4. Monkeypox Prevalence, By Region

6. Global Monkeypox Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))
  • 6.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
  • 6.2.3. By Company (2021)
  • 6.2.4. By Region
• 6.3. Product Market Map

7. North America Monkeypox Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Monkeypox Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By End User
  • 7.3.2. Canada Monkeypox Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By End User

8. Europe Monkeypox Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. United Kingdom Monkeypox Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By End User
  • 8.3.2. Germany Monkeypox Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By End User
  • 8.3.3. France Monkeypox Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By End User
  • 8.3.4. Belgium Monkeypox Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By End User
  • 8.3.5. Netherlands Monkeypox Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By End User
  • 8.3.6. Sweden Monkeypox Therapeutics Market Outlook
    • 8.3.6.1. Market Size & Forecast
      • 8.3.6.1.1. By Value
    • 8.3.6.2. Market Share & Forecast
      • 8.3.6.2.1. By Treatment
      • 8.3.6.2.2. By End User
  • 8.3.7. Italy Monkeypox Therapeutics Market Outlook
    • 8.3.7.1. Market Size & Forecast
      • 8.3.7.1.1. By Value
    • 8.3.7.2. Market Share & Forecast
      • 8.3.7.2.1. By Treatment
      • 8.3.7.2.2. By End User
  • 8.3.8. Spain Monkeypox Therapeutics Market Outlook
    • 8.3.8.1. Market Size & Forecast
      • 8.3.8.1.1. By Value
    • 8.3.8.2. Market Share & Forecast
      • 8.3.8.2.1. By Treatment
      • 8.3.8.2.2. By End User

9. Asia-Pacific Monkeypox Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. Australia Monkeypox Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By End User
  • 9.3.2. Singapore Monkeypox Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By End User

10. Middle East and Africa Monkeypox Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. Nigeria Monkeypox Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

• 13.1. Company Profiles
  • 13.1.1. Company Details
  • 13.1.2. Financials (As reported)
  • 13.1.3. Key Market Focus and Geographical Presence
  • 13.1.4. Pricing of Target Products
  • 13.1.5. Market positioning
• 13.2. Chimerix Inc.
• 13.3. SIGA Technologies, Inc.
• 13.4. Emergent BioSolutions Inc.
• 13.5. Bavarian Nordic A/S
• 13.6. Hetero Drugs Limited
• 13.7. Mylan N.V.
• 13.8. Piramal Enterprises Limited
• 13.9. Olon S.p.A.
• 13.10. Teva Pharmaceutical Industries Limited
• 13.11. CIDIC Company Limited

14. Strategic Recommendations

(Note: The companies list can be customized based on the client requirements.)